Company: SRPT
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0000950170-25-029973
Chunk: 514

Company: Sarepta Therapeutics, Inc.
Filing Date: 2025-02-28
Form: 10-K
Item: Item 8
Chunk 514
---
 (1,163
    )

    11,778

    Changes in operating assets and liabilities, net:

    Increase in accounts receivable

    (201,661
    )

    (185,699
    )

    (61,638
    )

    (Increase) decrease in manufacturing-related deposits and prepaids

    (188,588
    )

    (12,521
    )

    42,557

    Increase in inventory

    (395,170
    )

    (147,714
    )

    (50,780
    )

    (Increase) decrease in other assets

    (9,676
    )

    1,808

    (27,937
    )

    Decrease in deferred revenue

    (32,160
    )

    (86,828
    )

    (89,244
    )

    Increase (decrease) in accounts payable, accrued expenses,   lease liabilities and other liabilities

    110,649

    (50,135
    )

    147,572

    Net cash used in operating activities

    (205,787
    )

    (500,993
    )

    (325,346
    )

    Cash flows from investing activities:

    Purchase of property and equipment

    (136,956
    )

    (76,106
    )

    (30,824
    )

    Purchase of available-for-sale securities

    (1,099,595
    )

    (2,044,940
    )

    (1,936,856
    )

    Maturity and sales of available-for-sale securities

    2,002,112

    1,868,482

    923,224

    Purchase of intangible assets

    (10,000
    )

    (11,239
    )

    (1,427
    )

    Acquisition of strategic investments

    —

    (4,000
    )

    (1,000
    )

    Proceeds from sale of Priority Review Voucher

    —

    102,000

    —

    Net cash provided by (used in) investing activities

    755,561

    (165,803
    )

    (1,046,883
    )

    Cash flows from financing activities:

    Settlement of capped call share options for 2024 Notes

    45,349

    80,645

    26,317